Managing residual risk in patients receiving statin therapy

Mann, Marilyn K

doi:10.5694/j.1326-5377.2011.tb04158.x

Topics

To the Editor: I am writing about important errors contained in a letter of reply by Hamilton-Craig.1 In his response to a letter by Montgomery,2 he states:

Division of Investment Management, US Securities and Exchange Commission, Washington, DC, USA.

Correspondence: mannm@comcast.net

1. Hamilton-Craig IR. Managing residual risk in patients receiving statin therapy [letter]. Med J Aust 2010; 193: 375-376. <MJA full text>
2. Montgomery BD. Managing residual risk in patients receiving statin therapy [letter]. Med J Aust 2010; 193: 375. <MJA full text>
3. Rossebø AB, Pedersen TR, Boman K, et al; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343-1356.
4. Kastelein JJ, Akdim F, Stroes ES, et al; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-1443.

Online responses are no longer available. Please refer to our instructions for authors page for more information.